Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Available from: / ViewArticle.aspx?ArticleId=21169

In this issue

Home Eurosurveillance Edition  2014: Volume 19/ Issue 16 Article 6
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 19, Issue 16, 24 April 2014
Research articles
Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11)
  1. Health Protection Surveillance Centre, Dublin, Ireland
  2. Vaccine European New Integrated Collaboration Effort (VENICE) Project
  3. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  4. Centers for Disease Control and Prevention, Atlanta, United States
  5. Istituto Superiore di Sanitá, Rome, Italy
  6. French Institute for Public Health Surveillance (Institut de Veille Sanitare, InVS), Saint-Maurice, France
  7. CINECA Consortium of Universities, Bologna, Italy
  8. Statens Serum Institut, Copenhagen, Denmark
  9. National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland
  10. The gatekeepers are listed at the end of the article

Citation style for this article: Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber JT, D'Ancona F, Lévy-Bruhl D, Dematte L, Giambi C, Valentiner-Branth P, Stankiewicz I, Appelgren E, O’Flanagan D, the VENICE project gatekeepers group. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro Surveill. 2014;19(16):pii=20780. Article DOI:
Date of submission: 12 February 2013

Since 2008, annual surveys of influenza vaccination policies, practices and coverage have been undertaken in 29 European Union (EU)/ European Economic Area (EEA) countries. After 2009, this monitored the impact of European Council recommendation to increase vaccination coverage to 75% among risk groups. This paper summarises the results of three seasonal influenza seasons: 2008/09, 2009/10 and 2010/11. In 2008/09, 27/29 countries completed the survey; in 2009/10 and 2010/11, 28/29 completed it. All or almost all countries recommended vaccination of older people (defined as those aged ≥50, ≥55, ≥59, ≥60 or ≥65 years), and people aged ≥6 months with clinical risk and healthcare workers. A total of 23 countries provided vaccination coverage data for older people, but only 7 and 10 had data for the clinical risk groups and healthcare workers, respectively. The number of countries recommending vaccination for some or all pregnant women increased from 10 in 2008/09 to 22 in 2010/11. Only three countries could report coverage among pregnant women. Seasonal influenza vaccination coverage during and after the pandemic season in older people and clinical groups remained unchanged in countries with higher coverage. However, small decreases were seen in most countries during this period.  The results of the surveys indicate that most EU/EEA countries recommend influenza vaccination for the main target groups; however, only a few countries have achieved the target of 75% coverage among risk groups. Coverage among healthcare workers remained low.


Influenza is a contagious viral respiratory infection, which typically occurs as epidemics during the winter months in temperate zones. Although the illness caused by influenza is usually self-limiting, even in those outside recognised risk groups, it can cause considerable impact on an individual’s daily life. At a population level, large numbers of cases with mild to moderate severity of illness increase demands on health services and decrease productivity in the workforce, with associated economic cost and social disruption [1-3]. The number of people affected varies from year to year among countries, making it hard to predict the annual number of deaths or economic impact.

Annual influenza epidemics are associated with high morbidity and mortality. The European Centre for Disease Prevention and Control (ECDC) estimates that on average nearly 40,000 people die prematurely each year from influenza in countries of the European Union (EU)/European Economic Area (EEA) covered by Vaccine European New Integrated Collaboration Efforts (VENICE). VENICE covers all EU/EEA countries except Lichtenstein [4]. Death has been reported in 0.5–1 per 1,000 cases of influenza, with the highest hospitalisation rates occurring among children less than two years of age and individuals ≥65 years in United States [5]. The most effective single public health intervention to mitigate and prevent seasonal influenza is vaccination [6]. Unlike the situation for most childhood vaccines, the European policy for influenza is protection of those at higher risk either directly by vaccinating them or indirectly by vaccinating those who are likely to infect them (healthcare workers (HCWs) and pregnant women). Vaccination of pregnant women protects the women during and immediately after pregnancy and also decreases the risk to their infant [7].

The primary indicators of success in implementation of vaccination programmes are the group coverages, i.e. the proportion of specific target populations who have been vaccinated. In December 2009, the European Council unanimously recommended that EU countries adopt and implement national action plans to achieve 75% influenza vaccination coverage in all at-risk groups by the influenza season of 2014/15 [8]. The selection of risk groups followed guidance from ECDC and recommendations of the World Health Organization (WHO): ‘older’ individuals (often defined as aged ≥65 years) and people of all ages above six months with underlying medical conditions [9-11], referred to in this article as clinical risk groups. This EU recommendation encouraged countries to adopt and implement national, regional or local action plans or policies to improve seasonal influenza vaccination including among HCWs and to measure coverage in all risk groups. Countries were also encouraged to report on a voluntary basis to the European Commission on the implementation of the recommendation. ECDC-supported VENICE surveys have been to be the most effective way of doing this without placing additional reporting burdens on countries [12,13].

The overall aim of this paper is to document progress towards achieving the 75% coverage target in risk groups in the EU/EEA Member States since the 2009 recommendation. More specific objectives are to provide an overview of data collected for pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11) influenza seasons in order to monitor the progress of specific items in the recommendation and to identify changes in country-specific vaccination recommendations for the targeted age and risk groups during this period and also to report on vaccination coverage in the first season after the 2009/10 pandemic across EU/EEA countries.


The methodology of the VENICE project influenza surveys has been previously described [14-16]. In November 2011, VENICE conducted the fourth seasonal influenza vaccination survey and collected data for the 2010/11 influenza season. This survey was a collaborative study between EU/EEA countries, ECDC and the VENICE project group.

A standard questionnaire (similar to those used in previous years) was amended to reflect additional information needs for the 2010/11 season. This can be seen in the full survey report [12,17]. Following a pilot phase, the questionnaire was placed on a restricted-access web platform. The questionnaire contained prefilled data from the previous survey relating to the 2009/10 season. Experts (gatekeepers) of all 27 EU Member countries plus Norway and Iceland identified in each country at the beginning of the VENICE project in 2006 were asked to update information on vaccination policies and action plans and were requested to provide the available vaccination coverage rates for the 2010/11 influenza season.

We sought accurate and validated information on population groups that were targeted for influenza vaccination (age, occupation, clinical risk or other groups, e.g. contacts of infants less than six months of age or immunosuppressed individuals), most recent (at the time of survey) vaccination coverage results by population group for the 2010/11 influenza season (or most recent season if not available) and planned policy or operational changes across countries expected in forthcoming years. National survey returns were validated by the gatekeepers with authorities in their ministries of health.

We present and compare vaccination coverage data for the older population, clinical risk groups, pregnant women and HCWs obtained from the three latest consecutive VENICE surveys. All data provided in this paper for the 2009/10 influenza season refer to seasonal influenza vaccination during the 2009/10 pandemic (coverage with the pandemic vaccines have already been reported by VENICE [17]). Influenza vaccination recommendations that are detailed by age group for the 2010/11 influenza season refer to vaccination regardless of other clinical risk indications. Vaccination coverage data in the countries covered by VENICE were provided for one, two or all three influenza seasons, depending on data availability in each country. The methods used (administrative or survey) to calculate vaccination coverage for people in clinical risk groups and HCWs [18] are recorded in this paper. For comparison of vaccination coverage, we did not use any statistical test.

Vaccination coverage data for the United Kingdom (UK) were provided separately for Northern Ireland, Wales, England and Scotland. In our analysis, the UK is counted as one country, but coverage data are presented for each part. Vaccination coverage for pregnant women in the UK was calculated separately for those who were healthy and those with a clinical risk indication.


Response rate
Of the 29 EU/EEA countries participating in the VENICE project, 27 provided data for 2008/09 influenza season (Bulgaria and Luxembourg did not respond to the survey); 28 countries reported data for 2009/10 season (the UK did not respond to the survey, but provided vaccination coverage data); 28 countries responded to the survey that collected data for the 2010/11 influenza season (Finland did not respond to the survey, but provided clarifying information regarding age groups recommended for vaccination for the 2010/11 season at the time of writing. Consequently, the number of countries in some parts of the results section in this paper was 29).

Policy initiatives
At the time of completion of the 2010/11 influenza seasonal survey (November 2011), it was reported that seven countries had updated a previous action plan and two had developed plans after the Council recommendation to improve seasonal influenza vaccination coverage by 2014/15. The Netherlands had already achieved the target coverage. There was no report of any action plan for 18 countries.

Vaccination recommendations
Age groups targeted for seasonal influenza vaccination
All 29 countries recommended seasonal influenza vaccination for the older-age population in 2010/11; however, the specified age differed between countries. Of the 29 countries, 20 recommended vaccination for individuals ≥65 years. In four countries (Germany, Greece, Iceland and the Netherlands), vaccination was recommended for those aged ≥60 years. Two countries (Malta and Poland) recommended vaccination for individuals ≥55 years; Slovakia recommended vaccination for individuals aged ≥59 years. The remaining two countries (Austria and Ireland) recommended vaccination for those ≥50 years. In Ireland, however, vaccination is only provided free of charge and vaccination coverage monitored for individuals aged ≥65 years. Detailed information on age groups targeted for the 2010/11 influenza season is presented in Table 1.

Table 1. Age groups recommended for seasonal influenza vaccination by EU/EEA countrya (n=29) in the 2010/11 influenza season

Of the 29 responding countries, eight (Austria, Estonia, Finland, Latvia, Malta, Poland, Slovakia and Slovenia) reported recommending seasonal influenza vaccination for various age groups of healthy children aged <18 years in the 2010/11 influenza season. In  Latvia and Slovenia, vaccination was recommended for children aged ≥6 months to 2 years; in Finland, vaccination was recommended for children aged ≥6 months to 3 years; in Malta, vaccination was recommended for children aged ≥6 months to 4 years; in Slovakia, vaccination was recommended for children aged <12 years. Austria, Estonia and Poland recommended vaccination for children aged ≥6 months to <18 years.

Only two countries reported changes in the age groups recommended for vaccination in the 2010/11 season compared with the 2009/10 season. Poland recommended vaccination for those <18 years in 2010/11, which had not been recommended in previous seasons. Hungary recommended vaccination for those aged ≥65 in 2010/11 instead of those aged ≥60 years as in 2009/10.

Clinical risk groups targeted for seasonal influenza vaccination in the 2010/11 season
All 28 responding countries in 2010/11 recommended vaccination for individuals with chronic pulmonary, cardiovascular and renal disease, those who were immunosuppressed due to disease or treatment and those with haematological and metabolic disorders. A total of 19 countries recommended vaccination for individuals with any condition compromising respiratory function.  Nine countries recommended vaccination for individuals with morbid obesity (body mass index ≥40 kg/m2).

In comparison with previous VENICE surveys and since the Council recommendation, a number of countries had made changes to their seasonal influenza vaccination recommendations and policies compared with previous seasons, specifically related to risk groups. The number of countries that recommended vaccination for pregnant women increased (16 countries in 2009/10 vs 22 countries in 2010/11). Of the 22 countries in 2010/11, 19 recommended vaccination for all pregnant women; three recommended vaccination for pregnant women with an additional clinical risk condition. A total of 13 countries recommended vaccination during the second or third trimester and nine countries recommended vaccination at any stage during pregnancy.

From 2009/10 to 2010/11, more countries included a recommendation that household contacts of people in clinical risk groups, older individuals or children less than 6 months of age should be vaccinated (e.g. 10 countries in 2009/10 vs 14 countries in 2010/11 for household contacts of individuals belonging to clinical risk groups; six countries in 2009/10 vs 11 countries in 2010/11 for household contacts of children less than 6 months of age) (Table 2). There were no substantial changes relating to recommendations regarding vaccination of members of occupational groups. Of the 28 responding countries, 20 recommended vaccination for all HCWs and five only to some HCWs in 2010/11 (the recommendations differed in these five countries: e.g. staff with close contact with patients; or staff with no contact with patients, but contact with potentially contaminated material; or social care staff directly involved in frontline patient care). Three countries did not recommend vaccination for HCWs.

Table 2. Population groups recommended for seasonal influenza vaccination in EU/EEA countriesa during three influenza seasons

Vaccination coverage rates
Overall, 23 countries provided vaccination coverage data. This is very similar to the situation before the Council recommendation (22 vs 23 countries for 2008/09 and 2010/11, respectively). Six countries (Austria, Belgium, Bulgaria, Cyprus, Czech Republic and Greece) were unable to provide any group-specific coverage data in any of three influenza seasons surveyed.

Healthy children and adolescents
Nine countries reported vaccination coverage data for a variety of age groups of children and adolescents calculated by administrative or survey methods for at least one of the three influenza seasons (Table 3). Six of these countries (Estonia, Finland, Latvia, Poland, Slovakia and Slovenia) recommended vaccination of children or adolescents, while three other countries (France, Italy and Portugal) provided vaccination coverage for some age groups although vaccination was not recommended for healthy children and adolescents in these countries. Two of the countries that recommended influenza vaccination for children did not provide vaccination coverage data (Austria and Malta).

Table 3. Vaccination coverage for seasonal influenza for children in nine European Union countriesa 


Older population groups
A total of 23 countries were able to provide vaccination coverage rates of their older population groups targeted for vaccination for two or three influenza seasons (2008/09, 2009/10 or 2010/11), i.e. notwithstanding the recommendations of the European Council and WHO, six countries were not gathering any age group-specific data on vaccination coverage. The data provided for each country refer to the specific age group defined by each country as constituting the older population (≥50, ≥55, ≥59, ≥60 or ≥65 years).

Vaccination coverage among older age groups ranged from 1% (Estonia) to 82% (the Netherlands) in 2008/09 influenza season. The highest reported vaccination coverage rates were in the Netherlands and some parts of the UK (England, Northern Ireland and Scotland) that achieved or almost achieved EU 2014/15 target. Five countries (France, Germany, Ireland, Italy and Spain) reported vaccination coverage around 60% for this specific age group. Denmark, Finland, Luxembourg, Malta, Norway, Portugal  and Sweden reported vaccination coverage around 50%. In six  countries (Hungary, Iceland, Lithuania, Romania, Slovakia and Slovenia) vaccination coverage was below 50%. In the remaining three countries (Estonia, Latvia and Poland), vaccination coverage was about 10% or less.

Comparing pre-pandemic, pandemic and post-pandemic influenza seasons, there were small decreases in vaccination coverage in half of the countries. In contrast, Ireland, Scotland and Wales reported coverage that was slightly higher in the post-pandemic influenza season in comparison with that during the pandemic (Figure 1).

Figure 1. Reported seasonal influenza vaccination coverage in oldera population in 23 EU/EEA countriesb during three influenza seasons


Clinical risk groups
Of 28 countries surveyed, seven were able to provide vaccination coverage rates for one, two or three influenza seasons for people in clinical risk groups. The coverage varied, ranging from approximately 29% in Ireland (2009/10) to 70% in the Netherlands (2010/11) and 80% in Northern Ireland (2009/10). In all countries that reported vaccination coverage rates, except the Netherlands and Northern Ireland, vaccination coverage was well below the 2014/15 EU target. The Netherlands almost achieved and Northern Ireland had already achieved the target.

Comparing pandemic and post-pandemic influenza seasons in some countries, there was a decrease in coverage of these risk groups (e.g. in Netherlands and Portugal); however, in others (e.g. Scotland), an increase in vaccination coverage was reported.

Overall, three Member States (Romania, Slovenia and the UK) were able to report vaccination coverage rates among pregnant women. The coverage was low in Romania and Slovenia (3.7% and 2.4%, respectively). In the UK, there was variation in reported coverage, which was calculated separately for healthy pregnant women (37% and 65% in England and Scotland, respectively) and for those with additional clinical risk factors (57% and 65% in England and Scotland, respectively) (Table 4).

Table 4. Vaccination coverage for seasonal influenza for clinical risk groups, pregnant women, residents of long-term healthcare facilities and healthcare workersa 

Healthcare workers
A total of 10 of the countries were able to report vaccination coverage for one, two or three influenza seasons for HCWs. The reported vaccination coverage varied, ranging from 12% (Norway and Wales in 2009/10) to 98% (Romania in 2008/09). In England, Hungary, Portugal and Scotland, coverage was between 30% and 50% in 2010/11. The remaining countries (France, Germany Norway, Slovenia, Spain and Wales), with exception of Romania, reported vaccination coverage ranged between 14% and 28% in 2010/11. When comparing the pandemic and post-pandemic influenza seasons, there was decrease in vaccination coverage in France, Germany, Hungary, Portugal and Spain, while increased vaccination coverage was reported in England, Wales and Norway. Detailed information is presented in Table 4.

Payment scheme for influenza vaccine
Older individuals (aged ≥50, ≥55, ≥59, ≥60 or ≥65 years, depending on the recommendation in specific countries) received influenza vaccine free of charge in 14 countries in 2010/11; seven of these countries reported vaccination coverage around 50% in older individuals.

Of seven countries that recommended vaccination for children in the 2010/11 influenza season, only two offered the vaccine free of charge (Malta and Slovakia). In four of them (Austria, Estonia, Poland and Slovenia), the full cost was paid by the recipient and in Latvia, the vaccine was partly funded.

The vaccine for members of clinical risk groups and HCWs was free of charge in 16 countries; for pregnant women and residents of long-stay care facilities, the vaccine was free of charge in 11 and 14 countries, respectively, in 2010/11 (Figure 2).

Figure 2. Payment scheme for influenza vaccine for different age, risk or target groups in EU/EEA countriesa in the 2010/11 influenza season


The analyses presented in this paper summarise information obtained from annual surveys implemented by VENICE among EU/EEA Member States. The results provide part of the data used to monitor progress following the 2009 Council recommendation [8]. Other relevant data were collected by the European Commission for an interim report which was prepared in 2013 [19].  The same data can also be used to monitor WHO recommendations for groups to be targeted for vaccination (revised in 2012)[20].

Interpretation of results for the period 2008/09 to 2010/11 is complicated as there was both the introduction of the seasonal influenza recommendation and the very varied experience of the pandemic and its vaccination campaigns across European countries [13,21,22]. Given the difficulties experienced with pandemic vaccination in some European countries, it is reassuring that coverage in the older age groups held up as well as it did in 2010/11. However, there has been little improvement in seasonal vaccination coverage in other risk groups despite national and the Council recommendations; in some countries, coverage has decreased. Since only nine countries in November 2011 reported having action plans to implement the Council recommendation, it may be that countries delayed implementing the recommendation, given their pandemic experience.

The challenges that countries face implementing national and Council recommendation varied and may be related to different knowledge, attitudes and practices, risk perception, health systems and related cost issues that differ by country across the region. In addition, media coverage and public debate about vaccine effectiveness, which depends on the match with circulating vaccine strains, can negatively impact vaccination coverage [23,24]. The experience of narcolepsy following use of pandemic vaccines in some EU/EEA countries undoubtedly had a negative impact on public perception of vaccine safety, which may also have led to subsequent decrease in coverage in some countries [25,26]. Anti-vaccination groups and media coverage may also have contributed to this decrease [27].

Many countries appear to have had difficulties monitoring coverage in target groups other than older people. This may be related to differences in health system delivery, how vaccination is implemented in the country and data collection or information systems available for capturing such data. What is possible in one country may not be easily adopted in another.

During and after the pandemic, a number of countries made changes to national recommendations regarding additional risk groups who would benefit from vaccination, influenced by collected epidemiological data during pandemic. More countries recommended vaccination of pregnant women and individuals with morbid obesity. Morbid obesity was recognised as an independent risk factor for hospitalisation and death due to pandemic influenza [28-30]. Before the pandemic, no EU/EEA country had included this group in recommendations for influenza vaccination.

There is currently no consensus within European countries regarding routine seasonal influenza vaccination of children, although such recommendation is now standard in the United States [31] and WHO is recommending vaccination of children ≥6 to 59 months of age [20]. Since the pandemic, more countries are adopting such recommendations [32]. The reluctance of countries to recommend routine seasonal influenza vaccination of children may reflect a lack of evidence regarding cost-effectiveness and risk perception of this measure [32]. Partially, this reflects that there are so few data from Europe. Even in those countries that have recommended seasonal vaccination of children for a number of years, the reasons for low coverage have not been explored in our study but it may reflect low risk perception among the public and the medical community. Live intranasal vaccines that do not require injection were licensed by the European Medicines Agency in 2010 and may increase acceptance and delivery of annual vaccination among those EU/EEA countries recommending vaccination for children [33].

The 2010/11 survey found an increase in the number of countries recommending seasonal influenza vaccination for pregnant women. This increase may reflect better awareness of influenza morbidity among pregnant women that was notably evident during the pandemic [34-36]. A body of literature has demonstrated the safety and effectiveness of vaccine in this group and there may also be benefits for the fetus and newborn child [37,38]. It is disappointing that only three of the 22 countries recommending vaccination of pregnant women were able to report coverage data for this high-risk population. In line with a growing consensus on the importance of vaccination for pregnant women, it is clear that this is an area in which countries should seek to improve information on programme implementation.

In operational terms, HCWs are a crucial group involved in influenza vaccination. They should be vaccinated to protect their patients; they have to give the vaccine and to advocate the vaccination to their patients. Repeated surveys have indicated that it is the opinion of the doctor or nurse that is most important in determining whether or not a person is immunised [39-41]. While most countries have long-standing recommendations to immunise HCWs with seasonal influenza vaccine, only a third could report vaccination coverage rates for any season. In addition, in most of these countries, coverage among HCWs is still low (with Romania and Hungary being the exceptions) and does not show signs of improvement. Moreover, it is surprising that coverage data for staff working in long-term care facilities were provided by only one country and coverage data for residents of such facilities was known in only two countries.

Costs associated with vaccine can be a deterrent or barrier for vaccination, particularly if the costs are borne by the individual [27]. We found that half of the countries surveyed have adopted a policy of provision of vaccine free of charge, in total or in part, predominantly for elderly people, individuals with chronic disease, pregnant women and HCWs. However, four of seven countries reported that the full cost is paid for vaccination of children.

Survey limitations
The survey data presented here have limitations. Comparison of vaccination coverage data is difficult across European countries as different methods of estimating coverage are often used; within a given country, comparisons between years may be difficult if methods or response rate differ by year. How countries enumerate the denominator data (numbers eligible for vaccination) is often difficult to determine, especially when it comes to less specific groups, such as the clinical risk groups and HCWs. The enumeration of numbers vaccinated (numerator data) also has limitations as countries may use either data provided from administrative records or immunisation registries or from others surveys, both of which may have their own limitations. While the surveys report exact details on how numerator and denominator data are calculated, the surveys do not explore or report the specific limitations. Denominator data for clinical risk groups are particularly difficult to estimate accurately for most EU/EEA countries, reflecting the lack of information systems (disease registers) or other standardised methodologies for collecting these data in the countries. Some countries have used population surveys to estimate the number of individuals at risk. But even this may not be comparable between countries as a variety of methodologies have been used (e.g. household surveys, mail, face to face, telephone interviews). The reasons for low or high uptake across EU/EEA countries were not collected in these surveys: future studies are needed.

Additional efforts are needed to increase vaccination coverage among older population groups, individuals with a clinical risk indication, pregnant women and HCWs in order to achieve the target of 75% by the winter of 2014/15. The continued low vaccination coverage levels reported for HCWs are of concern and highlight the need for more focused and intensive health promotion and implementation of vaccination campaigns.

Some countries have achieved coverage higher than the target and there is value in sharing information between countries on how this has been achieved. Additional country-level research is required to identify the reasons for non-vaccination so that specific issues can be addressed through more targeted promotion campaigns. All countries should strive to collect information on vaccination coverage for older age groups as well as those in other risk groups, without which monitoring progress is not possible.

VENICE gatekeepers
Austria: Christina Kral, Jean Paul Klein; Belgium: Pierre Van Damme, Martine Sabbe, Françoise Wuillaume; Bulgaria: Mira Kojouharova; Czech Republic: Bohumir Kriz, Jan Kyncl; Cyprus: Chrystalla Hadjianastassiou, Soteroulla Soteriou; Denmark: Palle Valentiner-Branth, Tyra Grove Krause, Hanne-Dorte Emborg; England: Richard Pebody; Estonia: Natalia Kerbo, Irina Filippova; Finland: Tuija Leino; France: Daniel Levy-Bruhl, Isabelle Bonmarin; Germany: Sabine Reiter, Ole Wichmann; Greece: Theodora Stavrou; Hungary:-Zsuzsanna Molnàr; Iceland: Thorolfur Gudnason; Ireland: Suzanne Cotter; Italy: Fortunato D’Ancona, Caterina Rizzo; Latvia: Jurijs Perevoscikovs; Lithuania: Egle Savickiene; Luxembourg: Berthet Francoise; Malta-Tanya Melillo; the Netherlands: Bianca Snijders, Hester de Melker; Northern Ireland: Brian Smyth; Norway: Berit Feiring; Poland: Iwona Stankiewicz; Portugal: Paula Valente, Teresa Fernandes; Romania: Rodica Popescu; Scotland: Jim McMenamin ; Slovakia: Helena Hudecova; Slovenia: Alenka Kraigher, Veronika Učakar; Spain: Aurora Limia, Isabel Pachon del Amo; Sweden: Annika Linde; Wales: Simon Cottrell.

The gatekeepers are also listed in the 2010/11 report on the VENICE website [17].

We would like to acknowledge all the gatekeepers who provided data from each Member State and those in the ministries of health who validated the returns.

Conflict of interest
None declared.

Authors’ contributions
The work presented here was carried out in collaboration between all authors. AN, DOF, PL and TN defined the research theme. JM, SC, DA and TW worked on designing methods for survey and developing survey tool, interpreted results. JM analysed data, interpreted results and wrote the draft manuscript. AN, DLB, CG, PVB, IS and EA provided their comments, participated in discussions, writing the manuscript. LD contributed providing IT support. Gatekeepers completed a questionnaire in each EU/EEA Member State. All authors have contributed to, seen and approved the manuscript.


  1. de Blasio BF, Xue Y, Iversen B, Gran JM. Estimating influenza-related sick leave in Norway: was work absenteeism higher during the 2009 A(H1N1) pandemic compared to seasonal epidemics? Euro Surveill. 2012;17(33):pii=20246. 
  2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-96.
  3. Schanzer DL, McGeer A, Morris K. Statistical estimates of respiratory admissions attributable to seasonal and pandemic influenza for Canada. Influenza Other Respi Viruses. 2013 Sep;7(5):799-808.
  4. Nicoll A, Ciancio BC, Lopez Chavarrias V, Mølbak K, Pebody R, Pedzinski B, et al. Influenza-related deaths--available methods for estimating numbers and detecting patterns for seasonal and pandemic influenza in Europe. Euro Surveill. 2012;17(18):pii=20162.
  5. Centers for Disease Control and Prevention (CDC). Influenza. Epidemiology and prevention of vaccine preventable diseases. The pink book: course textbook. 12th ed. Second printing. Atlanta, GA: CDC; May 2012. Available from:
  6. Nicoll A, Sprenger M. Low effectiveness undermines promotion of seasonal influenza vaccine. Lancet Infect Dis. 2013;13(1):7-9.
  7. Poehling KA, Szilagyi PG, Staat MA, Snively BM, Payne DC, Bridges CB, et al. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol. 2011;204(6 Suppl 1):S141-8.
  8. Commission of the European Communities. Proposal for a Council recommendation on seasonal influenza vaccination. Brussels; Commission of the European Communities; 2009. Available from:
  9. Nicoll A, Ciancio B, Tsolova S, Blank P, Yilmaz C. The scientific basis for offering seasonal influenza immunisation to risk groups in Europe. Euro Surveill. 2008;13(43):pii=19018.
  10. World Health Organization (WHO). Prevention and control of influenza pandemics and annual epidemics. Resolution of the Fifty-Sixth World Health Assembly WHA56.19. Tenth plenary meeting, 28 May 2003. Geneva: WHO. [Accessed 4-Jan-2013]. Available from: 
  11. Influenza vaccines. Wkly Epidemiol Rec. 2005;80(33):279-87.
  12. Vaccine European New Integrated Collaboration Effort (VENICE). National seasonal influenza vaccination survey in Europe, 2007/2008 influenza season. Collaboration between VENICE project and ECDC. VENICE II. July - October 2009. [Accessed 1 Apr 2012]. Available from:
  13. Vaccine European New Integrated Collaboration Effort (VENICE). Pandemic A(H1N1) 2009 influenza vaccination survey, influenza season 2009/2010. VENICE II consortium. August 2010-April 2011. VENICE. [Accessed 1 Apr 2013]. Available from:
  14. Mereckiene J, Cotter S, Nicoll A, Levy-Bruhl D, Ferro A, Tridente G, et al. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill. 2008;13(43):pii=19017.
  15.  Mereckiene J, Cotter S, Weber JT, Nicoll A, Lévy-Bruhl D, Ferro A, et al. Low coverage of seasonal influenza vaccination in the elderly in many European countries. Euro Surveill. 2008;13(41):pii=19001.
  16. Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill. 2010;15(44):pii=19700.
  17. Vaccine European New Integrated Collaboration Effort (VENICE). Seasonal influenza vaccination in EU/EEA,influenza season 2010-11. VENICE II consortium. September 2011‐March 2012 VENICE. [Accessed 23 Nov 2012]. Available from:
  18. World Health Organization (WHO). Immunization coverage. Immunization, Vaccines and Biologicals. Geneva: WHO. [Accessed 1 Apr 2013]. Available from:
  19. European Commission (EC). Commission staff working document.State of play on implementation of the Council Recommendation of 22 December 2009 on seasonal influenza vaccination (2009/1019/EU). Brussels: EC; 2014. Available from:
  20.  Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87(47):461-76.
  21.  European Comission (EC). Assessment report on EU-wide pandemic vaccine strategies. 25 August 2010. Brussels: EC. [Accessed 1 Apr 2013]. Available from:
  22. Mereckiene J, Cotter S, Weber JT, Nicoll A, D'Ancona F, Lopalco PL, et al. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. Euro Surveill. 2012;17(4):pii=20064.
  23. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One. 2011;6(11):e27622.
  24. Kissling E, Valenciano M; I-MOVE case-control studies team. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro Surveill. 2011;16(11):pii=19818.
  25. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012;7(3):e33536.
  26. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31(8):1246-54.
  27. Kardas P, Zasowska A, Dec J, Stachurska M. Reasons for low influenza vaccination coverage: cross-sectional survey in Poland. Croat Med J. 2011;52(2):126-33.
  28. Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR
  29. Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis. 2011;52(3):301-12.
  30. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One. 2010;5(3):e9694.
  31. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
  32. European Centre for Disease Prevention and Control (ECDC). ECDC scientific advice on seasonal influenza vaccination of children and pregnant women. Stockholm: ECDC; 2012. Available from:
  33. European Medicines Agency (EMA). Fluenz influenza vaccine (live attenuated, nasal). Summary of opinion1 (initial authorisation). 21 October 2010. London: EMA; 2010. EMA/CHMP/503333/2010. Available from:
  34. Hardy JM, Azarowicz EN, Mannini A, Medearis DN Jr, Cooke RE. The effect of Asian influenza on the outcome of pregnancy, Baltimore, 1957-1958. Am J Public Health Nations Health. 1961;51:1182-8.
  35. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148(11):1094-102.
  36. Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerg Infect Dis. 2008;14(1):95-100.
  37. Moro PL, Broder K, Zheteyeva Y, Walton K, Rohan P, Sutherland A, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol. 2011;204(2):146.e1-7.
  38. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359(15):1555-64.
  39. Mereckiene J, O'Donnell J, Collins C, Cotter S, Igoe D, O'Flanagan D. Risk groups and uptake of influenza and pneumococcal vaccine in Ireland. Euro Surveill. 2007;12(12):pii=756.
  40. Müller D, Szucs TD. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Infection. 2007;35(5):308-19.
  41. Szucs TD, Müller D. Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons. Vaccine. 2005;23(43):5055-63.

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.